加味升降散对膜性肾病大鼠肾保护作用及对肾组织线粒体活性氧表达的影响
|
摘要
目的:观察加味升降散对膜性肾病(MN)大鼠模型血液生化指标及对肾线粒体活性氧(ROS)表达的影响。方法:将60只SD雄性大鼠,适应性喂养7 d后随机分为4组,造模成功后西药组给予盐酸贝那普利(10 mg·kg~(-1)·d~(-1))灌胃,中药治疗组给予加味升降散(13.22 g·kg~(-1)·d~(-1))灌胃,模型组和正常组给予同等剂量的生理盐水灌胃。4周后,生化试剂盒测定各组大鼠24 h尿蛋白定量(UTP),血清总胆固醇(TC),甘油三酯(TG),总蛋白(TP),白蛋白(ALB),尿素氮(BUN),肌酐(SCr),实时荧光定量聚合酶链式反应(Real-time PCR)测定大鼠肾组织线粒体ROS mRNA的表达。结果:与正常组比较,其余各组造模后UTP,TC,TG均升高(P<0.01),TP,ALB显著下降(P<0.05);治疗后,加味升降散组、盐酸贝那普利组与正常组比较,血液生化指标及对肾线粒体ROS均改善,但未恢复正常水平。治疗结束后,与模型组比较,加味升降散组、盐酸贝那普利组UTP,TC,TG均有所降低(P<0.05),加味升降散组、盐酸贝那普利组TP,ALB均有所升高(P<0.05)。加味升降散组与盐酸贝那普利组UTP,TC,TG,TP,ALB比较无统计学意义。治疗结束后,与模型组比较,加味升降散组、盐酸贝那普利组大鼠肾组织中足细胞线粒体ROS mRNA的表达较模型组明显下调(P<0.05);加味升降散组与盐酸贝那普利组线粒体ROS mRNA比较差异无统计学意义。结论:加味升降散对膜性肾病大鼠的肾保护作用可能与其能够下调肾组织线粒体ROS mRNA表达,抑制足细胞凋亡、修复受损足细胞有关。
Objective:To detect the effect of modified Shengjiangsan on the expression of reactive oxygen species(ROS)in mitochondria of renal foot cells of rats,in order to study the mechanism of modified Shengjiangsan.Method:After be fed for 7 days,the 60 SD male rats were randomly divided into four groups:blank control group,model group,positive medicine group and traditional Chinese medicine(TCM)treatment group.After establishment of the rat model of membranous nephropathy,model group,positive medicine group and TCM treatment group were treated differently.After 4 weeks,all of the rats were put to death,and the expressions of ROS,24-hour urinary protein quantity,total cholesterol,triglyceride,total protein,albumin,urea nitrogen,creatinine were detected by Real-time fluorescence quantitative polymerase chain reaction Real-time PCR.Result:The expression of 24-hour urinary protein quantity,total cholesterol,triglyceride in positive medicine group and TCM treatment group were reduced,and the expressions of total protein,albumin in positive medicine group and TCM treatment group were reduced compared with those of model group(P<0.05).The expressions of 24-hour urinary protein quantity,total cholesterol,triglyceride,total protein,albumin in TCM treatment group have no difference with those of positive medicine group.After treatment,the expression of ROS mRVA in mitochondria of renal foot cells of rats of positive medicine group and TCM treatment group were increased compared with that of model group(P<0.05),but with no difference in the ROS mRNA expression between positive medicine group and TCM treatment group.Conclusion:Modified Shengjiangsan can effectively control the development of ROS in mitochondria of renal foot cells of rats,and repair the renal function of membranous nephropathy rats by recovering foot cells.
Objective:To detect the effect of modified Shengjiangsan on the expression of reactive oxygen species(ROS)in mitochondria of renal foot cells of rats,in order to study the mechanism of modified Shengjiangsan.Method:After be fed for 7 days,the 60 SD male rats were randomly divided into four groups:blank control group,model group,positive medicine group and traditional Chinese medicine(TCM)treatment group.After establishment of the rat model of membranous nephropathy,model group,positive medicine group and TCM treatment group were treated differently.After 4 weeks,all of the rats were put to death,and the expressions of ROS,24-hour urinary protein quantity,total cholesterol,triglyceride,total protein,albumin,urea nitrogen,creatinine were detected by Real-time fluorescence quantitative polymerase chain reaction Real-time PCR.Result:The expression of 24-hour urinary protein quantity,total cholesterol,triglyceride in positive medicine group and TCM treatment group were reduced,and the expressions of total protein,albumin in positive medicine group and TCM treatment group were reduced compared with those of model group(P<0.05).The expressions of 24-hour urinary protein quantity,total cholesterol,triglyceride,total protein,albumin in TCM treatment group have no difference with those of positive medicine group.After treatment,the expression of ROS mRVA in mitochondria of renal foot cells of rats of positive medicine group and TCM treatment group were increased compared with that of model group(P<0.05),but with no difference in the ROS mRNA expression between positive medicine group and TCM treatment group.Conclusion:Modified Shengjiangsan can effectively control the development of ROS in mitochondria of renal foot cells of rats,and repair the renal function of membranous nephropathy rats by recovering foot cells.
引文
[1]陈惠萍,曾彩虹,胡伟新,等. 10 594例肾活检病理资料分析[J].肾脏病与透析肾移植杂志,2000,9(6):501-509.
[2]刘刚,马序竹,邹万忠,等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21(12):834-838.
[3]Honkanen E,Tornroth T,Gronhagen-Riska C. Natural history,clinical course and morphological evolution of membranous nephropathy[J]. Nephrol Dial Transplant,1992,7(1):35-41.
[4]Murphy B F, Fairley K F, Kincaid-Smith P S.Idiopathic membranous glomerulonephritis:long-term follow-up in 139 cases[J]. Clin Nephrol,1988,30(4):175-181.
[5]刘颖斐,王秋红,赵宏,等.车前子多糖治疗大鼠膜性肾病的实验探讨[J].中国实验方剂学杂志,2016,22(22):103-107.
[6]李莲花,陈新昌,张佩青.张佩青教授治疗膜性肾病用药规律挖掘研究[J].中国实验方剂学杂志,2016,22(12):205-208.
[7]王刚,袁国栋,檀金川.益肾通络方对膜性肾病大鼠肾保护作用的研究[J].辽宁中医杂志,2012,39(4):742-744.
[8]檀金川,田力铭.益肾通络方对膜性肾病大鼠肾组织中NF-κB,MMP-2表达的影响[J].中国老年学杂志,2010,30(21):3111-3114.
[9]陈文军,陈素枝,靳晓华,等.降脂通络软胶囊对膜性肾病大鼠肾保护作用及对肾组织Bcl-2和Bad表达的影响[J].中草药,2016,47(18):3263-3268.
[10]Border W A,Ward H J,Kamil E S,et al. Inducion of membranous nephropathy in rabbits by administration of an exogenous cationic antigen[J]. J Clin Invest,1982,69(2):451-461.
[11]梁静,孙兴旺,曹灵,等.不同剂量阳离子化牛血清白蛋白对膜性肾病大鼠造模的影响[J].中国组织工程研究与临床康复,2008,12(37):7322-7325.
[12]刘玲玲,徐维玮.环磷酰胺治疗特发性膜性肾病的疗效[J].肾脏病与透析肾移植杂志,2018,27(2):182-186.
[13]宋爱凤,杨巧芳,沈敬华,等.足细胞损伤与膜性肾病的研究进展[J].中国医药科学,2013,3(23):49-51.
[14]杨丽影,杨巧芳,薛昕,等.加味过敏煎不同拆方组分对膜性肾病大鼠足细胞裂孔膜蛋白Nephrin的影响[J].中华中医药杂志,2017,32(12):5562-5565.
[15]皇甫冰,高继萍,杨霞,等.氧化应激与肾脏细胞凋亡[J].中国比较医学杂志,2015,25(2):54-59.
[2]刘刚,马序竹,邹万忠,等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21(12):834-838.
[3]Honkanen E,Tornroth T,Gronhagen-Riska C. Natural history,clinical course and morphological evolution of membranous nephropathy[J]. Nephrol Dial Transplant,1992,7(1):35-41.
[4]Murphy B F, Fairley K F, Kincaid-Smith P S.Idiopathic membranous glomerulonephritis:long-term follow-up in 139 cases[J]. Clin Nephrol,1988,30(4):175-181.
[5]刘颖斐,王秋红,赵宏,等.车前子多糖治疗大鼠膜性肾病的实验探讨[J].中国实验方剂学杂志,2016,22(22):103-107.
[6]李莲花,陈新昌,张佩青.张佩青教授治疗膜性肾病用药规律挖掘研究[J].中国实验方剂学杂志,2016,22(12):205-208.
[7]王刚,袁国栋,檀金川.益肾通络方对膜性肾病大鼠肾保护作用的研究[J].辽宁中医杂志,2012,39(4):742-744.
[8]檀金川,田力铭.益肾通络方对膜性肾病大鼠肾组织中NF-κB,MMP-2表达的影响[J].中国老年学杂志,2010,30(21):3111-3114.
[9]陈文军,陈素枝,靳晓华,等.降脂通络软胶囊对膜性肾病大鼠肾保护作用及对肾组织Bcl-2和Bad表达的影响[J].中草药,2016,47(18):3263-3268.
[10]Border W A,Ward H J,Kamil E S,et al. Inducion of membranous nephropathy in rabbits by administration of an exogenous cationic antigen[J]. J Clin Invest,1982,69(2):451-461.
[11]梁静,孙兴旺,曹灵,等.不同剂量阳离子化牛血清白蛋白对膜性肾病大鼠造模的影响[J].中国组织工程研究与临床康复,2008,12(37):7322-7325.
[12]刘玲玲,徐维玮.环磷酰胺治疗特发性膜性肾病的疗效[J].肾脏病与透析肾移植杂志,2018,27(2):182-186.
[13]宋爱凤,杨巧芳,沈敬华,等.足细胞损伤与膜性肾病的研究进展[J].中国医药科学,2013,3(23):49-51.
[14]杨丽影,杨巧芳,薛昕,等.加味过敏煎不同拆方组分对膜性肾病大鼠足细胞裂孔膜蛋白Nephrin的影响[J].中华中医药杂志,2017,32(12):5562-5565.
[15]皇甫冰,高继萍,杨霞,等.氧化应激与肾脏细胞凋亡[J].中国比较医学杂志,2015,25(2):54-59.